Group 1: Company Growth and Innovation Strategies - The company is focusing on establishing innovation platforms with renowned research institutions to enhance high-value new drug development and accelerate results transformation [2][3] - There are over 100 drugs in the research pipeline, including multiple first-class innovative drugs like OAB-14 for Alzheimer's treatment [3][4] - The company aims to deepen internationalization and strengthen its position in the high-value raw material drug market [2][3] Group 2: Financial Performance and Market Position - In 2024, the company achieved a revenue of 8.466 billion yuan, representing a year-on-year growth of 4.51% [6][9] - The company emphasizes cash dividends, with the cash dividend ratio significantly exceeding the stipulated proportion in its articles of association [2][3] - The company's price-to-earnings ratio is lower than most pharmaceutical companies, raising concerns about potential stock buybacks [2][6] Group 3: Cost Control and Efficiency Measures - The company implements comprehensive budget management to control expenses and enhance operational efficiency [3][4] - Measures include optimizing procurement processes and production operations to reduce costs while maintaining quality [3][4] Group 4: Market Challenges and Stock Performance - Despite the approval of multiple new products, the stock price has been declining, influenced by market competition, industry policies, and investor sentiment [5][9] - The company acknowledges the impact of macroeconomic uncertainties and competitive pressures on its market value [9][10] Group 5: Investor Relations and Communication - The company is committed to enhancing communication with investors through regular reports and performance briefings [6][9] - The recent investor relations activities aim to rebuild investor confidence and clarify the company's strategic direction [6][9] Group 6: Industry Outlook - The pharmaceutical industry is expected to grow due to increasing health awareness and an aging population, with innovation driving new drug development [11]

Financial Performance - The total operating revenue for the fiscal year 2024 reached RMB 8,466,309,803.08, representing a 4.51% increase compared to RMB 8,100,844,707.33 in 2023[10] - The net profit attributable to shareholders of the listed company decreased by 5.33% to RMB 470,023,746.08 from RMB 496,512,201.25 in the previous year[10] - The basic earnings per share for 2024 was RMB 0.69, a decrease of 6.76% from RMB 0.74 in 2023[10] - The company proposes a final dividend of RMB 0.25 per share for the year 2024, based on a total issued share count of 689,776,535 shares[19] - The company reported a total comprehensive income of RMB 542,947,084.11, compared to RMB 507,843,039.72 in the previous year, representing an increase of 6.9%[77] - The net profit for the year was RMB 486,714,573.88, a decrease of 3.1% compared to RMB 506,107,025.01 in 2023[77] - The total income tax expense for 2024 reached RMB 46,938,849.44, compared to RMB 26,578,700.01 in 2023, which is an increase of approximately 76.7%[107] - The company reported a total of RMB 187,662,099.63 in dividends for the year 2024, up from RMB 134,936,567.00 in 2023, indicating a growth of about 39.0%[112] Assets and Liabilities - The total assets as of the end of 2024 increased by 8.85% to RMB 9,019,601,567.53 compared to RMB 8,286,166,330.90 at the end of 2023[10] - The total liabilities increased by 8.31% to RMB 3,802,101,150.19 from RMB 3,510,413,044.14 in the previous year[9] - The company's asset-liability ratio stood at 42.15%[41] - The total debt of the company was RMB 1,663,214,000, with cash and cash equivalents amounting to RMB 1,245,023,000[38] - Current assets totaled RMB 3,726,840,162.91 as of December 31, 2024, compared to RMB 3,314,333,616.01 in the previous year, indicating an increase of about 12.48%[72] - The company reported a total inventory of RMB 1,272,856,947.10 as of December 31, 2024, slightly down from RMB 1,312,983,676.75 in 2023, indicating a decrease of about 3.06%[72] Cash Flow - The net cash flow from operating activities improved by 38.58% to RMB 367,610,448.95 from RMB 265,278,895.87 in 2023[10] - Cash and cash equivalents increased by 35.57% to ¥1,245,022,873.47 from ¥918,334,462.29, primarily due to increased bank deposits to meet investment needs[26] - Operating cash inflow increased by 16.06% to ¥8,190,329,183.85 from ¥7,057,191,280.19, driven by enhanced operational efficiency and faster inventory turnover[33] - The net increase in cash and cash equivalents was ¥355,190,755.19, a significant improvement of 255.05% compared to a decrease of ¥229,080,092.64 in the previous year[33] Shareholder Information - The number of registered shareholders as of December 31, 2024, was 76,496, including 39 H-share and 76,457 A-share shareholders[13] - The company issued an additional 7,368,900 A-shares due to the stock option incentive plan during the reporting period[8] - The total number of shares held by major shareholders includes 204,864,092 RMB ordinary shares and 193,314,147 overseas listed foreign shares[16] - The total number of shares held by directors and senior management as of December 31, 2024, is 2,055,050 shares, an increase from 1,215,250 shares in 2023[20] Market and Product Development - The company plans to continue expanding its market presence and invest in new product development to drive future growth[10] - The company achieved sales revenue from new pharmaceutical products, with 22 new formulation product approvals and 5 new raw material drug approvals during the year[45] - The company plans to launch over 50 new products in the next two years, providing strong support for innovation breakthroughs and goal completion by 2025[50] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[85] Operational Efficiency - The company reported a 25.05% decrease in selling expenses, totaling ¥584,739,997.94 compared to ¥780,171,394.31, reflecting cost control measures[30] - The company experienced a 76.60% increase in income tax expenses, amounting to ¥46,938,849.44, attributed to higher profitability in a higher tax rate environment[30] - The company’s liquidity ratios include a current ratio of 133.31% and a quick ratio of 87.78% as of December 31, 2024[37] Research and Development - Research and development expenses were RMB 413,182,811.71, slightly down from RMB 419,239,700.90 in 2023[76] - The goal is to obtain over 15 drug approvals in the year, enhancing the R&D and transformation capabilities of active pharmaceutical ingredients[54] - The company is advancing the development of innovative drugs like OAB-14 and optimizing production processes to enhance competitiveness[55] Strategic Initiatives - The company completed the acquisition of its wholly-owned subsidiary, Ronghua (Zibo) Property Service Co., Ltd.[38] - The company introduced a green channel mechanism for R&D and production transformation, enhancing development vitality and achieving the introduction of 1 Chinese Academy of Engineering academician and 2 national key talent project members[48] - The company’s strategic cooperation with leading enterprises in the commercial sector has deepened, enhancing its market control[46]

证券代码：000756 证券简称：新华制药 公告编号：2024-43 山东新华制药股份有限公司 第十一届董事会 2024 年第二次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届董事会 2024 年第二次临时会议通知于 2024 年 9 月 26 日以电邮形式发出，会议于 2024 年 9 月 30 日以书面传签方式召开。应到会董 事 9 名，实际参会董事 9 名。会议的召开符合有关法律、法规、规章和《公司章程》的规定。 9 名董事赞成本议案，0 票反对，0 票弃权。 该议案尚需提交股东大会审议。 二、审议通过关于召开 2024 年第一次临时股东大会的议案 见同日发布于巨潮资讯网（http://www.cninfo.com.cn）的《关于召开 2024 年第一次临时 股东大会的通知》公告。 9 名董事赞成本议案，0 票反对，0 票弃权。 备查文件： 第十一届董事会 2024 年第二次临时会议决议。 特此公告。 会议主要审议并通过了以下议案： 一、审议通过关于修订《公司章程》及相关议事规则的议案 见 ...

山东新华制药股份有限公司 关于修订《公司章程》及相关议事规则的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 证券代码：000756 证券简称：新华制药 公告编号：2024-45 山东新华制药股份有限公司（"公司"）于 2024 年 9 月 30 日召开第十一届董事会 2024 年第二 次临时会议，审议通过了《关于修订<公司章程>及相关议事规则的议案》，该议案尚需提交股东大 会审议。现将具体内容说明如下： 基于《境内企业境外发行证券和上市管理试行办法》2023 年 3 月 31 日开始实施，《到境外上 市公司章程必备条款》同时废止，根据现行有效的《中华人民共和国公司法》、《上市公司章程指 引》、《独立董事管理办法》等相关规定，并根据公司的实际情况以及结合公司规范运作的实践， 拟对《公司章程》及相关议事规则进行修订和完善，具体修订情况详见附件。 特此公告。 山东新华制药股份有限公司董事会 2024 年 9 月 30 日 1 附件一： 《公司章程》修订对照 | 本公司章程 | | | --- | --- | | 现行条款 | 修订后条款 | | 第一条 | ...

Financial Performance - The company's operating revenue for the six months ended June 30, 2024, was RMB 4,732,481,467.24, representing a 1.29% increase compared to RMB 4,672,269,049.13 for the same period in 2023[8]. - Total profit for the same period was RMB 303,363,837.69, a decrease of 8.61% from RMB 331,945,812.26 in the previous year[8]. - Net profit attributable to shareholders of the listed company was RMB 265,404,417.68, down 1.63% from RMB 269,807,157.85 in the prior year[8]. - The net cash flow from operating activities increased significantly by 284.49%, reaching RMB 77,401,054.87 compared to RMB 20,131,070.66 in the previous year[8]. - Operating revenue for the first half of 2024 reached RMB 4,732,481,467.24, a 1.29% increase compared to RMB 4,672,269,049.13 in the same period of 2023[55]. - Operating costs increased by 8.13% to RMB 3,547,931,805.24 from RMB 3,281,046,254.21 year-on-year[55]. - The gross profit margin decreased by 4.75 percentage points to 25.03% from the previous year[58]. - The company reported a net profit of RMB 303,363,837.69 for the first half of 2024, down from RMB 532,685,725.02 in the same period of 2023[59]. - The total comprehensive income for the period was RMB 300,093,254.25, compared to RMB 289,553,439.14, reflecting an increase of about 3.5%[100]. - The company reported a total comprehensive income of RMB 238,097,470.11 for the first half of 2024, down from RMB 358,104,139.33 in the same period last year[101]. Shareholder Information - The company plans to distribute an interim dividend of RMB 0.25 per 10 shares, based on a total share capital of 682,407,635 shares[5]. - The total number of shareholders is 86,475, including 39 H-share shareholders and 86,436 A-share shareholders[13]. - The total number of shares as of June 30, 2024, is 682,407,635, with 94.34% being unrestricted shares[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.02% of the shares, totaling 204,864,092 shares[14]. - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 28.33% of the shares, totaling 193,314,147 shares[14]. - The number of restricted circulating shares is 38,633,274, accounting for 5.66% of the total share capital[12]. - The number of unrestricted circulating shares is 643,774,361, accounting for 94.34% of the total share capital[12]. - The shareholding structure shows no changes in the controlling shareholder or actual controller during the reporting period[18]. - The total salary paid to directors, supervisors, and senior management during the reporting period is RMB 2,011,825, with an additional RMB 6,390,878 for exercised stock options[22]. - The total number of A-shares held by directors, supervisors, and senior management is 2,055,050, representing approximately 0.4216% of the total issued A-shares[19]. Employee Information - The total number of employees in the group as of June 30, 2024, is 7,064, with a total salary expenditure of RMB 410,054,000 for the half-year period[23]. - The employee distribution by function includes 3,873 production personnel, 643 engineering technicians, and 940 sales personnel[24]. - The educational background of employees shows that 1,893 have a university degree or higher, while 2,328 have a college degree[25]. - The company has conducted 46 training sessions in the first half of 2024, with 2,321 participants, focusing on various professional skills and safety knowledge[25]. - The company has no retired employees or bonuses distributed during the reporting period[23]. Research and Development - The company launched 7 new formulation products in the first half of 2024, with 12 additional products in the pipeline[38]. - The company obtained 14 new product approvals and 6 consistency evaluation approvals in the first half of 2024[40]. - The company completed Phase I clinical trials for the innovative drug OAB-14 targeting Alzheimer's disease[40]. - Research and development expenses rose by 2.72% to RMB 231,912,142.60 compared to RMB 225,778,632.69 in the previous year[55]. - The company has established a roadmap for 91 innovation breakthrough projects for 2024[41]. - The company aims to accelerate the development of new products and market expansion, targeting the launch of at least 20 new products by the end of the year[47]. Financial Position - Total assets as of June 30, 2024, amounted to RMB 8,733,859,124.56, reflecting a 5.40% increase from RMB 8,286,166,330.90 at the end of 2023[8]. - Total liabilities increased by 7.09% to RMB 3,759,211,551.82 from RMB 3,510,413,044.14 at the end of 2023[8]. - The asset-liability ratio of the group stands at 43.04% as of June 30, 2024, reflecting a stable capital structure[61]. - The total capital debt ratio is 29.42% and the net capital debt ratio is 8.46%, indicating a manageable level of debt[61]. - The total current assets reached RMB 3,638,665,068.80, an increase from RMB 3,314,333,616.01 as of December 31, 2023, representing a growth of approximately 9.8%[94]. - The accounts receivable increased to RMB 1,022,661,555.32 from RMB 699,877,948.91, reflecting a growth of about 46.1%[94]. - The total equity attributable to shareholders increased to RMB 4,754,065,944.57 from RMB 4,553,103,869.56, showing an increase of about 4.41%[95]. - The total liabilities of the company at the end of June 2024 were RMB 2,122,924,920.24, an increase from RMB 2,000,000,000.00, reflecting a growth of approximately 6.1%[106]. Environmental Compliance - The company reported a total wastewater discharge with a chemical oxygen demand (COD) concentration of less than 500 mg/L, with a total COD discharge of 111 tons per year[78]. - The company has implemented pollution discharge standards for various pollutants, ensuring compliance with environmental regulations[78]. - The company operates in compliance with the environmental protection department's regulations as a key pollutant discharge unit[77]. - The company has established three wastewater treatment facilities with a total capacity of 12,000 tons per day, and additional facilities at subsidiaries with capacities of 500 tons and 3,000 tons per day, ensuring compliance with wastewater discharge standards[81]. - The company has developed emergency response plans for environmental incidents, including fire, explosion, and hazardous material leaks[86]. Corporate Governance - The company has maintained compliance with corporate governance standards as per relevant regulations in China[67]. - The company confirmed compliance with corporate governance codes without any deviations during the reporting period[88]. - The audit committee reviewed the unaudited interim accounts for the six months ending June 30, 2024, and agreed with the financial accounting principles adopted[89]. - The company has committed to avoiding any business or activities that may lead to competition or conflicts of interest with its main business during the period of control by its major shareholder[69]. - The company ensures that all transactions with its subsidiaries and related parties are conducted on an equal, voluntary, and fair basis[70]. Risk Management - The group has implemented measures to mitigate risks related to industry policy changes, new drug development, and raw material price fluctuations[64][65][66]. - The company is enhancing compliance management and risk control systems to ensure safe development[49]. - The company has established risk response mechanisms for potential disputes related to the "Quanding Huajun" project[72]. Investment and Financing - The company has no plans for share buybacks, sales, or repurchases during the reporting period[74]. - The company raised RMB 7,724,800.00 through stock options exercised in January 2024, contributing to the increase in registered capital[111]. - The company reported a profit of RMB 8,182,200 from its financial investments during the reporting period[75]. - The company has not planned any major investments or acquisitions for the upcoming years[87]. Revenue Recognition - The company recognizes revenue when control of goods or services is transferred to the customer, indicating a focus on sales of pharmaceutical products[188]. - Domestic sales revenue is recognized upon delivery of goods to customers, ensuring that payment rights are established and collectible[189]. - For export sales, revenue is recognized when products are customs cleared and the company has obtained the necessary shipping documents, confirming control transfer[190].

证券代码：000756 证券简称：新华制药 公告编号：2024-40 山东新华制药股份有限公司 关于获得《药品补充申请批准通知书》等相关情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的己酮可可碱注射液（以下简称"本品"）《药品补充申请批准通知书》， 批准本品上市许可持有人转让补充申请。现将相关情况公告如下： 一、基本情况 药品名称：己酮可可碱注射液 剂型：注射剂 注册分类：化学药品3类 申请人：山东新华制药股份有限公司 申请事项：上市许可持有人变更 受理号：CYHB2401223 药品批准文号：国药准字H20243881 通知书编号：2024B03985 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事 项符合药品注册的有关要求，同意按照《药品上市后变更管理办法（试行）》相关规定，批 准本品上市许可持有人变更。 二、其他相关信息 规格：5ml: 0.1g 药品分类：处方药 本次交易事项不构成关联交易，也不构成《上市公司重大 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 1 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited (於中華人民共和國註冊成立之股份有限公司) (股份編號：00719) | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000756 证券简称：新华制药 公告编号：2024-33 山东新华制药股份有限公司 2023年周年股东大会、2024年第一次A股类别股东会议及 2024年第一次H股类别股东会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 特别提示： 1、公司2023年周年股东大会（"周年股东大会"）、2024年第一次A股类别股东会议（"A股类别 股东会议"）、2024年第一次H股类别股东会议（"H股类别股东会议"，连同周年股东大会及A股类别 股东会议以下统称"会议"）有否决议案的情形。《关于提请股东大会授权董事会全权办理以简易程 序向特定对象发行股票具体事宜的议案》未获股东通过。 2、周年股东大会、A股类别股东会议、H股类别股东会议不涉及变更前次股东大会决议的情形。 一、会议召开的情况 1、召开时间： 5、主持人：本公司董事长贺同庆先生 6、周年股东大会、A股类别股东会议、H股类别股东会议的召开符合《中华人民共和国公司法》、 1 《深圳证券交易所上市公司股东大会网络投票实施细则》和本公司《公司章程》等有关规定。 二、会议的出席情况 | | 出席现场会议 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-28 1、召开届次：2023 年度周年股东大会、2021 年第一次 A 股类别股东会议 2、召开时间 （1）现场会议召开时间 ①2023 年度周年股东大会：2024 年 6 月 26 日下午 2 时 ②2024 年第一次 A 股类别股东会议：2024 年 6 月 26 日下午 3 时（或紧随本公司 2023 年度周 年股东大会结束后） （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 6 月 26 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络 投票的时间为自 2024 年 6 月 26 日上午 9:15 至下午 15:00 期间的任意时间。 山东新华制药股份有限公司 关于召开 2023 年度周年股东大会、2024 年第一次 A 股类别股东会议的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 一、召开会议的基本情况 公司于 2024 年 4 月 25 日召开第十一届董事会第三次会议， ...

Financial Performance - Operating revenue for Q1 2024 was RMB 2,474,697,457.66, a decrease of 6.25% compared to RMB 2,639,665,769.78 in Q1 2023[2] - Net profit attributable to shareholders for Q1 2024 was RMB 141,879,437.62, down 6.41% from RMB 151,603,818.36 in Q1 2023[2] - Basic earnings per share for Q1 2024 were RMB 0.21, a decrease of 8.70% from RMB 0.23 in Q1 2023[3] - The total profit for Q1 2024 was RMB 168,771,522.02, compared to RMB 184,919,311.15 in Q1 2023, showing a decline in profitability[4] - Net profit attributable to the parent company was approximately $141.88 million, a decrease from $151.60 million in the previous period[5] - Total comprehensive income attributable to the parent company was approximately $142.69 million, compared to $159.49 million previously[5] - Basic earnings per share were $0.21, down from $0.23 in the prior period[5] - Total comprehensive income for the period was approximately $146.08 million, compared to $161.72 million previously[5] - Other comprehensive income after tax attributable to the parent company was approximately $807,373.60, down from $7.89 million previously[5] - The company reported a decrease in foreign currency translation adjustments, with a loss of approximately $(69,418.40)[5] Cash Flow and Assets - Net cash flow from operating activities improved significantly to RMB 38,063,364.43, compared to a negative RMB 183,742,803.27 in the same period last year, representing a 120.72% increase[2] - Total assets as of March 31, 2024, were RMB 8,467,977,386.18, reflecting a 2.19% increase from RMB 8,286,166,330.90 at the end of 2023[3] - Net assets attributable to shareholders increased by 4.65% to RMB 4,764,918,585.13 from RMB 4,553,103,869.56 at the end of 2023[3] Research and Development - Research and development expenses for Q1 2024 were RMB 141,905,763.44, compared to RMB 112,119,587.26 in Q1 2023, indicating a focus on innovation[4] Strategic Initiatives - The company plans to continue its market expansion and enhance product development strategies in the upcoming quarters[1] - The company continues to focus on strategic initiatives to enhance operational efficiency and market presence[5] Governance and Compliance - The board approved changes to accounting policies effective January 1, 2024, with no significant impact on the financial statements[6] - The company is committed to adhering to the new accounting standards as outlined by the Ministry of Finance[6] - The board of directors consists of a mix of executive and independent non-executive members, ensuring diverse governance[7] Profitability Metrics - The company reported a gross profit margin of approximately 5.89% for Q1 2024, down from 6.81% in Q1 2023[4]